{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:09:57Z","timestamp":1792130997979,"version":"4.4.0"},"reference-count":57,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Evidence is emerging to support an association between certain human leukocyte antigen (HLA) alleles and the risk of cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplant (allo\u2010HSCT). The primary aim of this study was to identify HLA alleles associated with resistance or susceptibility to CMV reactivation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied 586 adults who underwent allo\u2010HSCT for high\u2010risk hematological malignancies. High\u2010resolution HLA typing data were available for recipients and donors. HLA class I and II alleles observed at a frequency of &gt;5% in our population were included in the analysis. A CMV viremia level of more than 200 IU\/ml on weekly monitoring was considered to be indicative of CMV reactivation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow\u2010up time in surviving patients was 21 months (range 4\u201374 months). The cumulative incidence of CMV reactivation at 6 months in the entire cohort was 55% (95% confidence interval [CI] 50.8%\u201359.2%). Mismatched donors, increasing recipient age, occurrence of acute graft versus host disease and recipient CMV seropositivity were associated with an increased risk of CMV reactivation. HLA B*07:02 (hazard ratio 0.59, 95% CI 0.40\u20130.83) was associated with a decreased risk of CMV reactivation. Patients who developed CMV reactivation had a lower incidence of relapse, higher transplant\u2010related mortality (TRM) and lower overall survival (OS) than those without CMV reactivation. There was an adverse correlation of OS and TRM with increasing numbers of CMV reactivations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We observed that HLA B*07:02 was associated with a decreased risk of CMV reactivation. CMV reactivation was associated with lower relapse post\u2010transplant, but this did not translate into a survival benefit due to higher TRM.\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid13879-gra-0001-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text><\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.13879","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:11:51Z","timestamp":1655338311000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-8306","authenticated-orcid":false,"given":"Shruti","family":"Prem","sequence":"first","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-4312","authenticated-orcid":false,"given":"Mats","family":"Remberger","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Uppsala University and KFUE Uppsala University Hospital  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-8787","authenticated-orcid":false,"given":"Ahmad","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun Datt","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-4911","authenticated-orcid":false,"given":"Dennis (Dong Hwan)","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2956-0848","authenticated-orcid":false,"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Al\u2010Shaibani","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Howard","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-4669","authenticated-orcid":false,"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-5699","authenticated-orcid":false,"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto, Section of Medical Oncology and Hematology  Toronto Ontario Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-5819","authenticated-orcid":false,"given":"Cynthia","family":"Ellison","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Transplant Program, Divison of HLA Laboratory Laboratory Medicine Program University Health Network  Toronto Ontario Canada"},{"name":"Department of Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-143560"},{"key":"e_1_2_9_3_1","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman P","year":"2006","journal-title":"Hematologica"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.221"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.08.010"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3616"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-487074"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.003"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00389"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-713644"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.019"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679639"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000142619.01510.A5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1079"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.003001008.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/597089"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2004.00054.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01591"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-005-5372-8"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705133"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003383"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4455"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07969.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.11.7569-7579.1996"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.9.5226-5240.2003"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01776"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(03)00028-4"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"e_1_2_9_29_1","first-page":"825","article-title":"Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw668"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-499830"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00936-09"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.04.017"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.023"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.12.327"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402748"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.5.2365"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-372003"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.374"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.191"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009362"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41409-020-0897-2","article-title":"Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta\u2010analysis of clinical outcome on behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAAWP of EBMT)","volume":"55","author":"El Gohary G","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.08.011"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383943"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-589150"},{"key":"e_1_2_9_48_1","first-page":"653","article-title":"Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG\u2010containing regimen","volume":"8","author":"Bao X","year":"2016","journal-title":"Am J Transl Res"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.4.1162.1162"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15515"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.478"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02849.x"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-203307"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.07.020"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2446-4"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0865-x"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.276352"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.113415"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13879","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.13879","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:02:31Z","timestamp":1755514951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.13879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/tid.13879"],"URL":"https:\/\/doi.org\/10.1111\/tid.13879","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"2022-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13879"}}